Dova Pharmaceuticals (DOVA) Major Shareholder Life Sciences Maste Perceptive Purchases 19,700 Shares

Dova Pharmaceuticals (NASDAQ:DOVA) major shareholder Life Sciences Maste Perceptive acquired 19,700 shares of the company’s stock in a transaction dated Monday, June 11th. The shares were purchased at an average cost of $29.36 per share, with a total value of $578,392.00. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Life Sciences Maste Perceptive also recently made the following trade(s):

  • On Friday, June 8th, Life Sciences Maste Perceptive acquired 25,000 shares of Dova Pharmaceuticals stock. The shares were purchased at an average cost of $28.65 per share, with a total value of $716,250.00.
  • On Wednesday, June 6th, Life Sciences Maste Perceptive acquired 100,000 shares of Dova Pharmaceuticals stock. The shares were purchased at an average cost of $28.66 per share, with a total value of $2,866,000.00.
  • On Monday, June 4th, Life Sciences Maste Perceptive purchased 10,000 shares of Dova Pharmaceuticals stock. The shares were bought at an average cost of $25.07 per share, for a total transaction of $250,700.00.

Shares of DOVA traded up $0.75 during mid-day trading on Thursday, hitting $30.05. 7,177 shares of the company traded hands, compared to its average volume of 199,723. Dova Pharmaceuticals has a one year low of $16.98 and a one year high of $37.00. The stock has a market capitalization of $833.90 million and a P/E ratio of -21.32.

Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings results on Wednesday, May 9th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.05). sell-side analysts anticipate that Dova Pharmaceuticals will post -2.18 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in DOVA. The Manufacturers Life Insurance Company grew its stake in shares of Dova Pharmaceuticals by 702.0% during the fourth quarter. The Manufacturers Life Insurance Company now owns 4,756 shares of the company’s stock valued at $137,000 after purchasing an additional 4,163 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Dova Pharmaceuticals by 148.6% in the first quarter. JPMorgan Chase & Co. now owns 5,345 shares of the company’s stock valued at $145,000 after acquiring an additional 3,195 shares during the last quarter. Jane Street Group LLC bought a new position in Dova Pharmaceuticals in the first quarter valued at approximately $220,000. Virtus Fund Advisers LLC bought a new position in Dova Pharmaceuticals in the fourth quarter valued at approximately $318,000. Finally, Deutsche Bank AG boosted its stake in Dova Pharmaceuticals by 139.2% in the fourth quarter. Deutsche Bank AG now owns 11,748 shares of the company’s stock valued at $337,000 after acquiring an additional 6,836 shares during the last quarter. 35.93% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have recently commented on DOVA. BidaskClub raised shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Evercore ISI began coverage on shares of Dova Pharmaceuticals in a research note on Friday, March 23rd. They set a “line” rating and a $29.00 price target on the stock. ValuEngine raised shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research raised shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 14th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $32.00.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Insider Buying and Selling by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply